IRIS

A study was carried out in six human volunteers, to assess the blood kinetics of isoniazid, rifampicin and pyrazinamide, administered in a fixed-triple combination intended for use in intermittent chemotherapy of tuberculosis. The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide. In each subject, the same dose of each drug was administered individually in separate sessions and the results compared. The results indicated that, at the level of dose of the intermittent tablet, no negative interactions between the drugs were observed.

Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.

LUISETTI, MAURIZIO;PEONA, VITTORIA;POZZI, ERNESTO;
1993-01-01

Abstract

A study was carried out in six human volunteers, to assess the blood kinetics of isoniazid, rifampicin and pyrazinamide, administered in a fixed-triple combination intended for use in intermittent chemotherapy of tuberculosis. The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide. In each subject, the same dose of each drug was administered individually in separate sessions and the results compared. The results indicated that, at the level of dose of the intermittent tablet, no negative interactions between the drugs were observed.
1993
Medical Research, Diagnosis & Treatment contains studies of existing and developing diagnostic and therapeutic techniques, as well as specific classes of clinical intervention. Resources in this category emphasize the difference between normal and disease states, with the ultimate goal of more effective diagnosis and intervention. Specific areas of interest include pathology and histochemical analysis of tissue, clinical chemistry and biochemical analysis of medical samples, diagnostic imaging, radiology and radiation, surgical research, anesthesiology and anesthesia, transplantation, artificial tissues, and medical implants. Resources focused on the disease, diagnosis, and treatment of specific organs or physiological systems are excluded and are covered in the Medical Research: Organs & Systems category.
MONALDI ARCHIVES FOR CHEST DISEASE
sì
Sì, ma tipo non specificato
Inglese
Nazionale
STAMPA
48
205
209
8369784
Adult, Biological Availability, Capsules, Drug Administration Schedule, Drug Combinations, Half-Life, Humans, Isoniazid; administration /&/ dosage/blood/pharmacokinetics/therapeutic use, Male, Pyrazinamide; administration /&/ dosage/blood/pharmacokinetics/therapeutic use, Rifampin; administration /&/ dosage/blood/pharmacokinetics/therapeutic use, Tablets, Tuberculosis; Pulmonary; drug therapy
6
info:eu-repo/semantics/article
262
G., Acocella; Luisetti, Maurizio; G. G., Grassi; Peona, Vittoria; Pozzi, Ernesto; C., Grassi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/357065
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact